Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer.
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer / Turner, N.C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K.e., Giorgetti, C., Randolph, S., Koehler, M., Cristofanilli, M., DE LAURENTIIS, M.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 373:3(2015), p. 209-19. [10.1056/NEJMoa1505270]
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
DE LAURENTIIS, MICHELINO
2015
Abstract
Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer.| File | Dimensione | Formato | |
|---|---|---|---|
|
nejmoa1505270.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
511.29 kB
Formato
Adobe PDF
|
511.29 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
